- ￥1126 - 3990
- Solarbio
- 北京
- IP6490
- 2026年02月09日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
PF-2771
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
2070009-55-9
- 规格：
10mg/5mg/1mg
| 规格： | 10mg | 产品价格： | ￥3990.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥2490.0 |
| 规格： | 1mg | 产品价格： | ￥1126.0 |
| 基本信息 | |
| CAS | No.2070009-55-9 |
| 英文名称 | PF-2771 |
| 分子式 | C29H36ClN5O4 |
| 分子量 | 554.08 |
| 溶解性 | Soluble in DMSO ≥3mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| SMILES | CC(C)OC1=C(C=C(C=C1)C(=O)NC(CC2=CC=C(C=C2)C3=CN(C(=N3)C(=O)C)C)CNC(=O)CN(C)C)Cl |
| InChIKey | VHBJNUOZEQTSNN-QHCPKHFHSA-N |
| InChI | InChI=1S/C29H36ClN5O4/c1-18(2)39-26-12-11-22(14-24(26)30)29(38)32-23(15-31-27(37)17-34(4)5)13-20-7-9-21(10-8-20)25-16-35(6)28(33-25)19(3)36/h7-12，14，16，18，23H，13，15，17H2，1-6H3，(H，31，37)(H，32，38)/t23-/m0/s1 |
| PubChem CID | 118704759 |
| 靶点 | Kinesin(CENP-E) |
| 通路 | Cytoskeleton |
| 背景说明 | PF-2771 是一种选择性的centromere protein E (CENP-E)抑制剂，具有抗肿瘤活性。 |
| 生物活性 | PF-2771 is a potent and selective centromere protein E (CENP-E) inhibitor， inhibiting CENP-E motor activity with an IC50 of 16.1 nM; PF-2771 is used as an anticancer agent.[1] |
| In Vitro | PF-2771 is a potent and selective CENP-E inhibitor， inhibiting CENP-E motor activity with an IC50 of 16.1 nM. PF-2771 shows no inhibitory effect on the ATPase activities of highly related kinesins (0% inhibition of Eg5/KSP， chromokinesin， and MCAK at both 1 or 10 μM PF-2771). PF-2771 exhibits inactive activity against 74 protein kinases (all cancer tumor cell survival， with EC50s of 50 > 5 μM). PF-2771 (100 nM) reusults in a chromosomal congression defect in MDA-MB-468 cells[1]. |
| 细胞实验 | PF-2771 (100 mg/kg， every day i.p.) potently inhibits CENP-E motor function， and causes tumor regression in SCID mice bearing AA1077 mammary tumors[1]. |
| 细胞实验 | PF-2771 is added to cells seeded in 96-well plates. The number of cells seeded (1，000-3，000) depended on growth characteristics of each cell type and normalized proliferation rates. Ten different concentrations of compound (PF-2771) used are based on a half-log increment between 1 nM and either 1 or 25 μM. Cells are incubated at 37°C for 7 days before assessing viability with the CellTiter-Glo reagent. Untreated control cells are 80% to 90% confluent after 7 days of culture. Data are fitted into a sigmoidal curve-fitting program to calculate IC50 values[1]. |
| 动物实验 | HCC1806 tumor cells (3 × 106) are implanted in the mammary fat pad of CB17/lcr.Cg-PrkdcscidLystbg female mice. PF-2771 is administered intraperitoneally (i.p.) to groups of 12 mice at 3， 10， and 30 mg/kg every day for 14 days and at 100 mg/kg every day for 4 days followed by 3 days off and then another 4-day cycle. Tumor volumes are recorded twice weekly by calipers with the final measurement taken 3 days after the last dose. Tumor growth inhibition (TGI) is calculated using the formula 100 × (1 ? ΔT/ΔC)， where ΔT (treated) and ΔC (control) are the mean tumor volume changes between 1 day after the last dose and the first-day treatment. Time-to-progression endpoint and associated tumor growth delay determinations are calculated using median days to reach to two doublings of initial tumor size. Statistical comparisons are made using one-way ANOVA with Dunnett posttests. Other tumor models had similar methodology except where noted. PDX-AA1077 is a patient-derived xenograft model developed from tumor tissue from a triple-negative patient engrafted to the mammary glands of NSG female mice to create passage 1 tumor-bearing mice. Surgically resected tumor tissue is cut into 2- to 4-mm3 fragments and subcutaneously implanted into the flank of SCID-bg mice. Mice with palpable tumors are randomized before dosing. An HCC1599 tumor cell line xenograft model is established from tumor fragments of established tumors and reimplanted into flank of female SCID mice. When average tumor size reached 250 mm3， animals are randomized into five groups of 10 mice. Animals are treated with vehicle (daily dosing)， 10 mg/kg docetaxel (once per week dosing)， 25 mg/kg docetaxel (once per week dosing)， 20 mg/kg paclitaxel (twice per week dosing)， or 100 mg/kg of PF-2771 (every day， i.p.)[1]. |
| 激酶实验 | Microtubule-activated CENP-E kinesin ATPase activity is measured spectrophotometrically by coupling the hydrolysis of ATP to ADP to NADH oxidation (decrease in 340 nm absorbance) through the activities of pyruvate kinase (PK) and lactate dehydrogenase (LDH). Reactions contained 2 mM phosphoenolpyruvate， 0.28 mM NADH， 5 mM MgCl2， 1 mM DTT， 15 μM taxol， 0.7 μM MT (preformed porcine microtubules)， 50 μM ATP， 10 U/mL PK， and 10 U/mL LDH in 15 mM PIPES buffer (pH 7.0). Reactions are initiated with a 20 nM CENP-E addition (Human: 1-342; WT) at 30°C. The IC50 values are determined by a nonlinear， least squares fit of the data to the four-parameter dose-response curve equation. PF-2771 kinesin biochemical selectivity toward other kinesins is tested in triplicate at both 1 and 10 μM PF-2771 in a variant of the CENP-E enzymatic assays that have the following enzyme concentrations: 200 nM chromokinesin motor domain， 200 nM Eg5 motor domain， 226 nM MCAK motor domain. PF-2771 biochemical mechanism is determined by measuring CENP-E enzymatic activity as a function of ATP and PF-2771 concentrations (0， 2.5， 5， 10， 20， 30， 45 nM PF-2771; 1，000， 500， 250， 125， 62.5， 31.2， 15.6， 7.81， 3.90， 1.95， 0.977 μM ATP)[1]. |
| 数据来源文献 | [1]. Kung PP， et al. Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer. Mol Cancer Ther. 2014 Aug;13(8):2104-15. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
（2）LD78和Act-2分别是人的MIP-1α和NIP-1β，与小鼠源性MIP-1α和NIP-1β有很高同源性。 （3）GROα、GROβ和GROγ指基因产物。 3.趋化因子作用特点 趋化因子C-X-C和C-C亚族的生物学活性有明显的差别。C-X-C亚族中，除γIP-10、Nig和PF-4外，其余成员均具有趋化和激活中性粒细胞的活性。编码这个亚族成员的基因定位于第4号染色体长臂，氨基酸水平上的同源性在25%～90%。γIP-10主要趋化单核细胞和T细胞。C-C亚族主要趋化
。通过产生PIP2, PTEN的功能远不止仅仅阻止AKT的作用。PIP2作为磷脂酶Cβ(PLCβ)的底物，产生DAG和IP3作为第二信使，升高胞内钙离子的水平并激活蛋白激酶C(PKC)。与膜结合的PIP2也能介导(增加)多种离子通道的活性，包括钙离子、钾离子和钠离子通道。PIP也参与到膜泡的形成以及细胞骨架与膜的相互作用过程中。PIP2还影响多种参与脂代谢的酶活性，包括磷脂酶D和神经酰胺-1-磷酸。通过从PIP产生PIP2, PTEN广泛的影响着细胞的多种功能途径。PTEN在减弱
多个，如TGF-β1、TGF-β2、TGF-β3、TGF-βlβ2以及骨形成蛋白(BMP)等。 6．趋化因子(chemokine) 趋化因子家族包括四个亚族：①C-X-C亚族或。亚族，主要趋化中性粒细胞，主要成员有IL-8、黑素瘤生长活性因子(GRO／MGSA)、血小板碱性蛋白(PBP)、干扰素诱导蛋白10(IP-IO)、基质衍生因子(SDF-1)、血小板因子4(PF-4)、ENA-78等；②C―C亚族或p亚族，主要趋化单核细胞。这个亚族的成员包括巨噬细胞炎症蛋白10(Mlbl0
技术资料暂无技术资料 索取技术资料
IP6490 PF-2771 细胞骨架 索莱宝
￥1126 - 3990
